All In Biotech

Drug Trial Radar · NCT02819635

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,302 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,302

Actual

Start

Sep 26, 2016

Primary completion

Dec 13, 2021

Study completion Dec 13, 2021

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction dose of upadacitinib for further evaluation in Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • PlaceboDrug

    Film-coated tablet for oral administration

  • UpadacitinibDrug

    Film-coated tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8Time frame: At Week 8
  2. Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8Time frame: At Week 8
  3. Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52Time frame: At Week 52

Locations

496 sites in 46 countries. Site status is shown where the registry gives one.

  • Birmingham Gastroenterology Associates P.C /ID# 151276

    Birmingham, Alabama

  • East View Medical Research, LLC /ID# 171183

    Mobile, Alabama

  • CB Flock Research Corporation /ID# 165980

    Mobile, Alabama

  • Delsol Research Management, Ll /Id# 170131

    Chandler, Arizona

  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211885

    Mesa, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 169822

    Sun City, Arizona

  • Adobe Clinical Research LLC /ID# 155250

    Tucson, Arizona

  • University of Arizona /ID# 150553

    Tucson, Arizona

  • Citrus Valley Gastroenterology /ID# 151914

    Covina, California

  • Newport Huntington Medical Group /ID# 217005

    Huntington Beach, California

  • UC San Diego Health System /ID# 155185

    La Jolla, California

  • United Medical Doctors /ID# 207464

    Los Alamitos, California

  • TLC Clinical Research Inc /ID# 216829

    Los Angeles, California

  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 157080

    Los Angeles, California

  • Facey Medical Foundation /ID# 203133

    Mission Hills, California

  • United Medical Doctors - Murrieta /ID# 151211

    Murrieta, California

  • InSite Digestive Health Care - Oxnard /ID# 163414

    Oxnard, California

  • Inland Empire Clinical Trials, LLC /ID# 216038

    Rialto, California

  • San Diego Clinical Trials /ID# 212120

    San Diego, California

  • Medical Assoc Research Grp /ID# 169148

    San Diego, California

  • Univ of California San Francis /ID# 164581

    San Francisco, California

  • Delta Waves, Inc. /ID# 151721

    Colorado Springs, Colorado

  • South Denver Gastroenterology /ID# 151223

    Lone Tree, Colorado

  • Western States Clinical Res /ID# 158076

    Wheat Ridge, Colorado

  • Western Connecticut Medical Group /ID# 169210

    Danbury, Connecticut

  • Medical Research Center of CT /ID# 150482

    Hamden, Connecticut

  • Gastro Florida /ID# 155245

    Clearwater, Florida

  • Moonshine Research Center, Inc /ID# 152533

    Doral, Florida

  • Universal Axon Clinical Research /ID# 213461

    Doral, Florida

  • Palmetto Research, LLC /ID# 151716

    Hialeah, Florida

  • Nature Coast Clinical Research - Inverness /ID# 154064

    Inverness, Florida

  • Encore Borland-Groover Clinical Research /Id# 170912

    Jacksonville, Florida

  • SIH Research Mumtaz, Inc /ID# 163319

    Kissimmee, Florida

  • Cfagi Llc /Id# 202017

    Maitland, Florida

  • University of Miami /ID# 215441

    Miami, Florida

  • Advanced Pharma /ID# 151719

    Miami, Florida

  • New Horizon Research Center /ID# 152474

    Miami, Florida

  • Crystal Pharmacology Research /ID# 151841

    Miami, Florida

  • Coral Research Clinic /ID# 150444

    Miami, Florida

  • Advanced Research Institute, Inc /ID# 163098

    New Port Richey, Florida

Showing 40 of 496 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.